TIL therapy and CAR T therapy are both innovative immunotherapies that use a patient’s own T cells to fight cancer, but they differ in key ways. TIL therapy focuses on T cells naturally found in a patient’s tumor. These cells, already primed to recognize the cancer, are collected, expanded in the lab, and then reintroduced to strengthen the body’s attack. On the other hand, CAR T therapy involves modifying T cells from the patient’s blood. These cells are genetically engineered to carry synthetic receptors that specifically target cancer cells, providing them with new capabilities to recognize and destroy the tumor. While TIL therapy is most effective for solid tumors like melanoma, CAR T therapy has shown success in blood cancers like leukemia. Both approaches have unique advantages but come with complexities, including specialized production processes and potential side effects. 

 

​